Send me real-time posts from this site at my email

May 7 - Trading List: Updates, Analyst Actions, Our Take - AUPH, EPZM

Aurinia Pharmaceuticals price target lowered to $23 from $26 at RBC Capital

RBC Capital analyst Douglas Miehm lowered the firm's price target on Aurinia Pharmaceuticals to $23 from $26 and keeps an Outperform rating on the shares.

Our Take:  "Aurinia got hit as m any people where betting on a buyout which did not happen. Also some read into the earnings report and were expecting better. We say give it patience. This is a longer-term hold if you believe in their lupus drug. The stock closed just above $10, our trade idea would be to sell some case covered $10 strike puts."

Epizyme upgraded to Outperform from Market Perform at SVB Leerink

SVB Leerink analyst Andrew Berens upgraded Epizyme to Outperform from Market Perform with a price target of $16, up from $12.

Our Take:  "Epizyme had a big bounce up day here on Friday. My guess is decent earnings news and an upgrade sent the short sellers covering. Stock jumped! This is a volatile little biotech. If playing it, trade around your positions by selling some covered calls."

$EPZM, Epizyme, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)!

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue